Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide Open Label Extension in Crohn's Disease
NCT00308438Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2004
- Primary completion
- Nov 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of teduglutide in Crohn's disease, sponsored by Takeda. Primary endpoint: Percentage of subjects in remission (CDAI score < 150) at 12 weeks. Started Mar 2004; status: completed.
02
Drugs
teduglutide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00308438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308438.